Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivation and Astellas Pharma have announced the treatment of first patient in a Phase 2 study of MDV3100, a triple-acting oral androgen receptor antagonist, in the treatment of advanced prostate cancer patients who have progressed while on LHRH analogue therapy or following surgical castration.
Subscribe to our email newsletter
The Phase 2 study is designed to compare MDV3100 with bicalutamide – a commonly used anti-androgen, and is expected to enroll approximately 370 patients in North America and Europe.
The primary endpoint of the trial is progression-free survival.
Astellas Pharma Global Development president Steven Ryder said this is the first of two Phase 2 trials in earlier stage disease that is being initiated to evaluate the potential benefit of MDV3100 in a broad spectrum of prostate cancer patients.
"The second of our new Phase 2 trials will study MDV3100 in an even earlier-stage population, and we expect to begin the trial in the first half of this year," Ryder said.
MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation) and inhibits binding to DNA.